Company: INMB
Filing Date: 2025-03-27
Form Type: 10-K
Source: 0001013762-25-003354
Chunk: 708

Company: Inmune Bio, Inc.
Filing Date: 2025-03-27
Form: 10-K
Item: Item 6
Chunk 708
---
 and other investors paid $8.32 per share and warrant.

During the year ended December
31, 2024, the Company received $0.4 million in exchange for the exercise of 108,000 stock options.

Item 7A. Quantitative and Qualitative Disclosures
about Market Risk

We are exposed to market risk
from changes in foreign currency rates.

66

Item 8. Financial Statements and Supplementary
Data

INDEX TO CONSOLIDATED FINANCIAL STATEMENTS

      Page  AUDITED FINANCIAL STATEMENTS:             REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM (PCAOB ID Number 688)    F-2         CONSOLIDATED BALANCE SHEETS AS OF DECEMBER 31, 2024 AND 2023   F-3         CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS FOR THE YEARS ENDED DECEMBER 31, 2024 AND 2023   F-4         CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS’ EQUITY FOR THE YEARS ENDED DECEMBER 31, 2024 AND 2023   F-5         CONSOLIDATED STATEMENTS OF CASH FLOWS FOR THE YEARS ENDED DECEMBER 31, 2024 AND 2023   F-6         NOTES TO CONSOLIDATED FINANCIAL STATEMENTS   F-7 

F-1

Report of Independent Registered Public Accounting Firm

To the Stockholders and Board of Directors of

INmune Bio Inc.

Opinion on the Financial Statements

We have audited the accompanying consolidated
balance sheets of INmune Bio Inc. (the “Company”) as of December 31, 2024 and 2023, the related consolidated statements
of operations and comprehensive loss, changes in stockholders’ equity and cash flows for each of the two years in the period ended
December 31, 2024, and the related notes (collectively referred to as the “financial statements”). In our opinion, the financial
statements present fairly, in all material respects, the financial position of the Company as of December 31, 2024 and 2023., and the
results of its operations and its cash flows for each of the two years in the period ended December 31, 2024, in conformity with accounting
princip